Omega Therapeutics announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. Most recently, Certel served as the Chief Business Officer at BioCity Biopharma, where he led the expansion of the global business development function and coordinated efforts to establish collaborations for the development of pipeline assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
- Omega Therapeutics presents new preclinical data at ASGCT 2024
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
- Omega Therapeutics sees cash runway into 1Q25
- Omega Therapeutics reports Q2 EPS (36c), consensus (33c)